Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort [0.03%]
新版瘤种通用型新辅助治疗病理学反应评估指南:SITC和INMC的联合倡议
J S Deutsch,R A Scolyer,E Burton et al.
J S Deutsch et al.
Background: Practice-changing clinical trials for novel therapeutic regimens administered in the neoadjuvant setting have been reported for multiple cancer types, bringing this treatment strategy to the forefront for pati...
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study [0.03%]
Datopotamab德鲁昔单抗与化疗在先前接受过治疗的不可切除/转移性激素受体阳性HER2阴性乳腺癌中的比较：TROPION-Breast01三期研究的最终总生存分析
B Pistilli,K Jhaveri,S-A Im et al.
B Pistilli et al.
Background: The TROPION-Breast01 study (NCT05104866) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with the TR...
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial [0.03%]
分子选择性西妥昔单抗再挑战治疗转移性结直肠癌的CAVE-2 GOIM随机试验
D Ciardiello,G Martini,L Boscolo Bielo et al.
D Ciardiello et al.
Background: Anti-epidermal growth factor receptor (EGFR) drug rechallenge could be of therapeutic value in a subgroup of refractory metastatic colorectal cancer (mCRC). ...
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC] [0.03%]
低剂量帕博利珠单抗联合化疗与单纯化疗新辅助治疗局部三阴性乳腺癌（TNBC）的II期、开放标签、随机研究[PLANeT试验-低剂量帕博利珠单抗联合NACT用于TNBC]
A Arora,H Bhaskarane,G Tansir et al.
A Arora et al.
Background: Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard of care treatment in non-metastatic triple negative breast cancer (TNBC). Trials employing reduced doses of immune checkpoint inhibito...
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al [0.03%]
两种试验的故事：TAILORx和PlanB。关于陈等人发表的“蒽环类药物在基因高危、腋窝阴性、HR阳性/HER2阴性乳腺癌中的影响”的信件回复
Oleg Gluz,Ronald Kates,Sherko Kuemmel et al.
Oleg Gluz et al.
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial [0.03%]
Capivasertib联合紫杉醇作为转移性三阴性乳腺癌一线治疗的疗效：随机、全球III期CAPItello-290试验结果
P S Schmid,H L McArthur,J Cortés et al.
P S Schmid et al.
Background: Adding the pan-AKT inhibitor capivasertib to first-line paclitaxel in metastatic triple-negative breast cancer (TNBC) led to significantly longer progression-free survival (PFS) and overall survival (OS) versu...
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test [0.03%]
精准的AKT靶向治疗在晚期前列腺癌中的阿喀琉斯之踵：被检测方法限制的发展前景
Emily Grist,Christopher J Sweeney,Gerhardt Attard
Emily Grist
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway is frequently activated in many cancers, including prostate cancer where this is often following loss of phosphatase and tensin homolog (PTEN). The CAPItello-281 trial is t...
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
局部和局淋巴结区域前列腺癌：诊断、治疗和随访欧洲肿瘤内科学会临床实践指南
J Walz,G Attard,A Bjartell et al.
J Walz et al.
R Govindan,K Navo,M Huang et al.
R Govindan et al.
Background: Germline alterations and smoking status in lung cancer could inform etiology and clinical decisions. We explored germline alteration prevalence in predisposition genes across lung cancer histologies from two l...
Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions [0.03%]
下一代多中心研究：使用人工智能跨多家机构自动处理肺癌患者无结构化健康记录
M Aldea,L Zullo,V Levrat et al.
M Aldea et al.
Background: Manual abstraction of real-world data (RWD) from unstructured health records (HRs) remains resource-intensive, error-prone, and highly variable across institutions. Large language models (LLMs) offer a scalabl...